Meg Poxon

RevMed with huge news for pancreatic cancer (daraxonrasib). The headline is hard to ignore 👀 • Median OS 13.2 vs 6.7 months • HR ~0.4 📉 • Activity across KRAS variants (not just G12C) • Manageable safety If that signal is real, this isn’t incremental. It changes how we think about KRAS. But—caveat applies ⚠️ This is a press release! PR as a rule is rosier than real data. Still… an OS HR like that gets your attention. Feels like we may be moving from mutation-specific inhibition → broader KRAS control. That’s the difference between niche utility and something that touches CRC, pancreas, lung… everything we see. Now we wait for the data behind the headline. @TheGutOncLab @OncoAlert @Onco_Nexus ir.revmed.com/news-releases/…

🚨🚨🚨 RASOLUTE-302 Ph3 is POSITIVE "Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW! AMAZING news for patients with #PancreaticCancer The RAS Revolution is ON!! ir.revmed.com/news-releases/…

Online Now: Emerging landscape of KRAS inhibitors in cancer treatment dlvr.it/TQdwB0

An update to the Hallmarks of Cancer framework for understanding (and researching) what causes human cancers. spkl.io/6010Aqwbi Douglas Hanahan @CellCellPress

Really pleased to share that I’ve been awarded Associate Fellowship of the Higher Education Academy (AFHEA). A great chance to reflect on my teaching and keep strengthening my work with students. Thanks to everyone who supported me along the way. #AFHEA #HigherEducation

Thank you @PancreaticCanUK for an insightful Discovery & Translational Research Forum. Including an inspiring talk by @SheffieldUni’s Ameera Jailani on the importance of collaboration in PC research, and a powerful PPIE session highlighting why this work matters. #PCUKForum2025.

The normal pancreas has hundreds of PanINs – they're like the moles of the pancreas (almost all of them have KRAS mutations) The risk of progression per PanIN is extremely small, but ~85% of pancreatic cancers form from PanINs This presents an opportunity for early detection and prevention of pancreatic cancer

Very excited to share our preprint on #AI directed Deep Visual Proteomics (DVP) on #PancreaticCancer precursor lesions (PanINs), in collaboration with @OmicVision @MundAndreas Thousands of proteins from as few as ~100 precisely microdissected cells in archival samples!

My sister has been sending me views from home - very much missing the lambs next door 🐑🌞

It was once again my turn to bake for our weekly joint lab meeting - this time I decided to lean into the cowboy theme 🤠🌞

Inhibiting FGFR2 Supports Prevention and Delay of Common Pancreatic Cancer Researchers from @CSHL have identified a new mechanism to delay KRAS-mutated pancreatic #cancer development in mice. hubs.ly/Q03fLrDy0

Had a fantastic time at the @Co_Biologists Biologists @ 100 conference, celebrating the 100 year anniversary! Ft plenty of exciting talks (including our very own @ZheBao_Sheff), posters and fun networking events ⭐

🚨Long term postdoc position available on the reconstitution of lipid kinases!🚨 Do you have a passion for protein reconstitution and lipid signalling? You will reconstitute lipid kinases to determine their kinetic regulation. jobs.ac.uk/job/DLW981/res…

It was time for a new work mug #yeehaw

You know it’s time to call it quits when your images start looking like Wolf Alice albums in your head

The NHS is lowering the bowel cancer screening age in England from 60 years to 50 years with the aim of detecting cancer at an earlier stage. The change involves sending home-testing kits which can identify signs of bowel cancer before symptoms appear to people aged 50 to 52.

Great day at #actin2024 featuring lots of v cool talks, including our very own @rachellawson954, @ZheBao_Sheff and @jtyler91 ✨

Check out my very impressive friend @jailani_ameera talk about pancreatic cancer and the important research her & her group do! open.spotify.com/episode/0TDoRH…

If you really love your protein of interest commit to a tattoo @ardemp

PI3K dependent rearrangement of the actin cytoskeleton following the addition of Class I PAK kinase-inhibitor. Please read about it in our pre-print!